摘要
目的:探讨慢性阻塞性肺疾病(COPD)急性发作合并肺炎患者采用痰热清注射液联合左氧氟沙星治疗的临床效果。方法:选取2022年7月—2023年6月滨州市中心医院收治的104例COPD急性发作合并肺炎患者,以随机数字表法分为研究组(n=52)与对照组(n=52)。对照组给予左氧氟沙星治疗,研究组给予痰热清注射液联合左氧氟沙星治疗。比较两组临床疗效、炎症因子、血气指标。结果:研究组治疗总有效率(92.31%)较对照组(76.92%)高,差异有统计学意义(P<0.05);治疗后两组C反应蛋白(CRP)、降钙素原(PCT)水平均下降,研究组均较对照组低,差异均有统计学意义(P<0.05);治疗后两组动脉血二氧化碳分压(PaCO_(2))均下降,动脉血氧分压(PaO_(2))均升高,研究组PaCO_(2)较对照组低,PaO_(2)较对照组高,差异均有统计学意义(P<0.05)。结论:痰热清注射液联合左氧氟沙星治疗COPD急性发作合并肺炎,能提高临床效果,缓解炎症反应,改善血气指标。
Objective:To explore the clinical effect of Tanreqing Injection combined with Levofloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease(COPD)complicated with pneumonia.Method:A total of 104 patients with acute exacerbation of COPD complicated with pneumonia admitted to Binzhou Central Hospital from July 2022 to June 2023 were selected and divided into study group(n=52)and control group(n=52)by random number table method.The control group was treated with Levofloxacin,and the study group was treated with Tanreqing Injection combined with Levofloxacin.The clinical efficacy,inflammatory factors and blood gas indexes were compared between the two groups.Result:The total effective rate of the study group(92.31%)was higher than that of the control group(76.92%),the difference was statistically significant(P<0.05).After treatment,C reactive protein(CRP)and procalcitonin(PCT)levels were decreased in both groups,and those in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,arterial partial pressure of carbon dioxide(PaCO_(2))decreased and arterial partial pressure of oxygen(PaO_(2))increased in both groups,PaCO_(2) in the study group was lower than that in the control group,and PaO_(2) was higher than that in the control group,the differences were statistically significant(P<0.05).Conclusion:Tanreqing Injection combined with Levofloxacin in the treatment of acute exacerbation of COPD complicated with pneumonia can improve clinical efficacy,relieve inflammatory reaction and improve blood gas indexes.
作者
马小芬
张莹
韩小莹
张学平
MA Xiaofen;ZHANG Ying;HAN Xiaoying;ZHANG Xueping(不详;Department of Respiratory and Critical Care Medicine,Binzhou Central Hospital,Binzhou 251700,China)
出处
《中国医学创新》
CAS
2024年第21期102-105,共4页
Medical Innovation of China
关键词
痰热清注射液
左氧氟沙星
慢性阻塞性肺疾病急性发作
肺炎
Tanreqing Injection
Levofloxacin
Acute exacerbation of chronic obstructive pulmonary disease
Pneumonia